EP2350263A4 - Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp) - Google Patents

Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Info

Publication number
EP2350263A4
EP2350263A4 EP09822721.8A EP09822721A EP2350263A4 EP 2350263 A4 EP2350263 A4 EP 2350263A4 EP 09822721 A EP09822721 A EP 09822721A EP 2350263 A4 EP2350263 A4 EP 2350263A4
Authority
EP
European Patent Office
Prior art keywords
lymphopoietin
tslp
thymic
stromal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09822721.8A
Other languages
German (de)
English (en)
Other versions
EP2350263A1 (fr
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2350263A1 publication Critical patent/EP2350263A1/fr
Publication of EP2350263A4 publication Critical patent/EP2350263A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
EP09822721.8A 2008-10-22 2009-10-22 Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp) Withdrawn EP2350263A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10745308P 2008-10-22 2008-10-22
US10748008P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061710 WO2010048425A1 (fr) 2008-10-22 2009-10-22 Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Publications (2)

Publication Number Publication Date
EP2350263A1 EP2350263A1 (fr) 2011-08-03
EP2350263A4 true EP2350263A4 (fr) 2013-07-03

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09822743.2A Withdrawn EP2364154A4 (fr) 2008-10-22 2009-10-22 Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
EP09822721.8A Withdrawn EP2350263A4 (fr) 2008-10-22 2009-10-22 Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09822743.2A Withdrawn EP2364154A4 (fr) 2008-10-22 2009-10-22 Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)

Country Status (9)

Country Link
EP (2) EP2364154A4 (fr)
JP (4) JP5688370B2 (fr)
CN (2) CN102256607B (fr)
AU (2) AU2009308302B2 (fr)
BR (2) BRPI0920201A2 (fr)
CA (2) CA2741341A1 (fr)
IL (2) IL212277A0 (fr)
MX (2) MX337035B (fr)
WO (2) WO2010048425A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (fr) 2006-10-25 2016-11-16 Revalesio Corporation Dispositif de mélange et procédé
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
BRPI0911612A2 (pt) * 2008-04-28 2015-12-15 Revalesio Corp composições e métodos para o tratamento da esclerose múltipla.
EP2285347A4 (fr) 2008-05-01 2011-09-21 Revalesio Corp Compositions et méthodes de traitement de troubles digestifs
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
NZ604063A (en) * 2010-05-07 2015-01-30 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
EP2696849A4 (fr) * 2011-04-13 2014-10-29 Revalesio Corp Compositions et procédés pour inhiber et/ou moduler des lymphocytes t effecteurs dans une maladie neurodégénérative inflammatoire
CN102250213B (zh) * 2011-07-01 2012-11-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
CN102268069B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂4及其应用
KR101492435B1 (ko) * 2012-12-28 2015-02-10 고려대학교 산학협력단 ＨＩＦ­１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
WO2019005948A1 (fr) 2017-06-27 2019-01-03 Translational Sciences, Inc. Inhibition de la métalloprotéinase matricielle 9 vasculaire pour traiter une lésion ischémique
CN114126623A (zh) * 2019-05-17 2022-03-01 宾夕法尼亚大学董事会 治疗肥胖和/或皮肤紊乱的方法和组合物
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
EP4788430A1 (fr) 2023-10-05 2026-08-12 Ashibio, Inc. Méthodes et compositions de traitement de troubles médiés par la mmp-9
WO2026076260A1 (fr) 2024-10-03 2026-04-09 Ashibio, Inc. Méthodes et compositions d'inhibition de mmp-9 destinées à être utilisées avec des troubles d'ossification hétérotopique non génétiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) * 2002-09-09 2004-03-18 Borsos Ferenc Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
WO2008018932A2 (fr) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006593A1 (fr) * 1998-07-28 2000-02-10 The Regents Of The University Of California Acides nucleiques codant les recepteurs associes a la proteine g qui interviennent dans la transduction sensorielle
CN1402642A (zh) * 1999-07-21 2003-03-12 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
EP1599165A4 (fr) * 2003-02-10 2010-09-08 Univ Jefferson Utilisation de ligands gcc
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (ko) * 2004-03-08 2006-05-24 양경숙 차륜 가변형 스쿠터
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20080014247A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
AU2007308840C1 (en) * 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
WO2008115290A2 (fr) * 2006-10-25 2008-09-25 Revalesio Corporation Méthodes de soins et de traitement de plaies
BRPI0911612A2 (pt) * 2008-04-28 2015-12-15 Revalesio Corp composições e métodos para o tratamento da esclerose múltipla.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) * 2002-09-09 2004-03-18 Borsos Ferenc Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
WO2008018932A2 (fr) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010048425A1 *

Also Published As

Publication number Publication date
JP5688370B2 (ja) 2015-03-25
EP2364154A4 (fr) 2013-07-10
JP2012506453A (ja) 2012-03-15
IL212309A0 (en) 2011-06-30
BRPI0920430A2 (pt) 2019-09-24
CA2741336A1 (fr) 2010-04-29
JP2015044869A (ja) 2015-03-12
JP2012506451A (ja) 2012-03-15
AU2009308302A1 (en) 2010-04-29
IL212277A0 (en) 2011-06-30
CN102256607A (zh) 2011-11-23
CN102257130A (zh) 2011-11-23
MX2011004233A (es) 2011-06-24
EP2364154A1 (fr) 2011-09-14
JP5688371B2 (ja) 2015-03-25
WO2010048425A1 (fr) 2010-04-29
MX337035B (es) 2016-02-09
AU2009308302B2 (en) 2016-01-21
EP2350263A1 (fr) 2011-08-03
WO2010048455A1 (fr) 2010-04-29
AU2009308362A1 (en) 2010-04-29
CN102256607B (zh) 2014-11-05
CN102257130B (zh) 2016-07-06
AU2009308362B2 (en) 2016-02-04
IL212309A (en) 2016-04-21
CA2741341A1 (fr) 2010-04-29
BRPI0920201A2 (pt) 2019-09-10
JP2015044868A (ja) 2015-03-12
MX2011004235A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
EP2352517A4 (fr) Procédés et compositions pour le traitement de troubles associés au complément
EP2214712A4 (fr) Compositions et procédés de traitement d'asthme et de troubles pulmonaires
EP2429530A4 (fr) Procédés et compositions de traitement de troubles dégénératifs et ischémiques
EP2341943A4 (fr) Compositions et procédés pour inhiber spécifiquement de l'expression d'un gène par modifications du traitement de l'arnds
EP2297341A4 (fr) Procédés et compositions pour le traitement de la maladie de huntington
EP2563406A4 (fr) Procédés, compositions et trousses pour le traitement de troubles de la minéralisation de la matrice
EP2544688A4 (fr) Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
EP2303227A4 (fr) Compositions de corticostéroïdes à libération contrôlée et procédés pour le traitement de troubles otiques
EP2209371A4 (fr) Compositions et procédés pour le traitement de la rétinopathie diabétique
EP2349320A4 (fr) Compositions et procédés destinés au traitement de troubles rénaux
EP2427575A4 (fr) Méthodes et compositions pour le diagnostic d'affections thyroïdiennes
EP2440559A4 (fr) Inhibiteurs d'egfr et procédés de traitement de troubles
EP2299979A4 (fr) Compositions antimicrobiennes à libération contrôlée et procédés pour le traitement de troubles otiques
EP2120580A4 (fr) Compositions et procédés de traitement de troubles métaboliques
EP2306975A4 (fr) Compositions à libération contrôlée modulant la structure otique et modulant le système immunitaire naturel et procédés de traitement de troubles otiques
EP2224955A4 (fr) Compositions et procédés pour la prévention et le traitement de l'arthrite
EP2043620A4 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
EP2203057A4 (fr) Procédés et compositions pour le traitement ou la prévention d'états inflammatoires
EP2259782A4 (fr) Formulations pharmaceutiques de resvératrol et procédés d'utilisation de celles-ci pour traiter des troubles cellulaires
EP1874286A4 (fr) Methodes et compositions pour le traitement de troubles anxieux
EP2349282A4 (fr) Procédés de traitement de troubles pulmonaires par des formulations liposomales d'amikacine
EP2688557A4 (fr) Procédés et compositions destinés au traitement du trouble déficitaire de l'attention
EP2490532A4 (fr) Nouvelles compositions pour prévenir et/ou traiter des troubles dégénératifs du système nerveux central
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
EP2355657A4 (fr) Compositions et procédés de traitement de troubles endothéliaux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVALESIO CORPORATION

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130531

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/573 20060101ALI20130524BHEP

Ipc: A61K 9/00 20060101AFI20130524BHEP

Ipc: A61K 33/00 20060101ALI20130524BHEP

17Q First examination report despatched

Effective date: 20140826

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170503